Genelux Corporation
GNLXNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
Analyst consensus ratings, 12-month price targets, and expert recommendations for Genelux Corporation stock.
Investment consensus from 3 professional research analysts
Loading chart...
Recent analyst recommendations with rating changes and price target updates (last 90 days)
| Date | Analyst | Firm | Action | Rating | Price Target |
|---|---|---|---|---|---|
| Dev Prasad | Lucid Capital | Initiates | Buy | $10.00 → $18.00 +8.00 (+80.0%) | |
| Jason McCarthy | Maxim | Maintains | Buy | $12.00 | |
| Emily Bodnar | HC Wainwright | Maintains | Buy | $31.00 |
Source: Professional analyst ratings and price targets from the last 90 days. Data as of Sep 16, 2026. Data sources and methodology
The analyst consensus rating for GNLX is Buy, based on the latest ratings from 3 analysts over the last 90 days.
The average 12-month price target for GNLX is $20.33, representing an upside of 740.1% from the Oct 16, 2026 close of $2.42.
Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.
A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.